Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors

Tagworks Pharmaceuticals BV Netherlands Massachusetts

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of tumor payload activityExpect to share preliminary data from the trial by early to mid-2026View original content:https://www.prnewswire.co.uk/news-releases/tagworks-pharmaceuticals-announces-initiation-of-third-dose-level-in-ongoing-phase-1-clinical-trial-of-tgw101-for-the-treatment-of-solid-tumors-302549978.html